Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease

Movement Disorders

Volumn 30, Issue 14, 2015, Pages 1893-1900

  Madhyastha, Tara M ^a   Askren, Mary K ^a   Boord, Peter ^a   Zhang, Jing ^b   Leverenz, James B ^c   Grabowski, Thomas J ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cerebral perfusion; Cortical thickness; Joint analysis; Multiple factor analysis; Parkinson's disease

Indexed keywords

ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN CORTEX; BRAIN PERFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE SEVERITY; FACTORIAL ANALYSIS; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE PROCESSING; INFORMATION PROCESSING; MALE; MIDDLE AGED; MIDDLE FRONTAL GYRUS; MILD COGNITIVE IMPAIRMENT; MOTOR SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; SPIN LABELING; AGED; ATROPHY; METABOLISM; ORGAN SIZE; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ATROPHY; CEREBRAL CORTEX; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGAN SIZE; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84955190889     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26128     Document Type: Article

References (39)

1. Watson GS, Leverenz JB. Profile of cognitive impairment in Parkinson's disease. Brain Pathol 2010;20:640-645. doi:10.1111/j.1750-3639.2010.00373.x.
2. Ma Y, Huang C, Dyke JP, et al. Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab 2010;30:505-509. doi:10.1038/jcbfm.2009.256.
3. Jubault T, Gagnon J-F, Karama S, et al. Patterns of cortical thickness and surface area in early Parkinson's disease. NeuroImage 2011;55:462-467. doi:10.1016/j.neuroimage.2010.12.043.
4. Pereira JB, Ibarretxe-Bilbao N, Marti M-J, et al. Assessment of cortical degeneration in patients with Parkinson's disease by voxel-based morphometry, cortical folding, and cortical thickness. Human Brain Mapping 2012;33:2521-2534. doi:10.1002/hbm.21378.
5. Lee PH, Yong SW, An Y-S. Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy. J Nucl Med 2008;49:2006-2011. doi:10.2967/jnumed.108.054668.
6. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211. doi:10.1016/S0197-4580(02)00065-9.
7. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Tredici KD. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134. doi:10.1007/s00441-004-0956-9.
8. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587-598. doi:10.1002/ana.23659.
9. Irwin DJ, Lee VM-Y, Trojanowski JQ. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci 2013;14:626-636. doi:10.1038/nrn3549.
10. Braak H, Rüb U, Del Tredici K. Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 2006;248:255-258. doi:10.1016/j.jns.2006.05.011.
11. Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007;6:926-932. doi:10.1016/S1474-4422(07)70245-4.
12. Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994;14:783-801. doi:10.1038/jcbfm.1994.99.
13. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 2007;34:714-723. doi:10.1016/j.neuroimage.2006.09.003.
14. Zarei M, Ibarretxe-Bilbao N, Compta Y, et al. Cortical thinning is associated with disease stages and dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84:875-881. doi:10.1136/jnnp-2012-304126.
15. Fernández-Seara MA, Mengual E, Vidorreta M, et al. Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI. Neuroimage 2012;59:2743-2750. doi:10.1016/j.neuroimage.2011.10.033.
16. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatr 2004;75:637-639.
17. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-580. doi:10.1002/ana.22311.
18. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
19. Cholerton B, Zabetian C, Quinn J, et al. Pacific Northwest Udall Center of Excellence clinical consortium: study design and baseline cohort characteristics. J Parkinson's Dis 2013;3:205-214. doi:10.3233/JPD-130189.
20. Watson GS, Cholerton BA, Gross RG, et al. Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. Alzheimer's & Dementia 2013;9:609-614. doi:10.1016/j.jalz.2012.07.006.
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Army Individual Test Battery: Manual of Directions and Scoring. Washington, DC: War Department, Adjutant General's Office, 1944.
23. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 1982;298:199-209.
24. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Oxford, NY: Oxford University Press, 2006.
25. Wechsler D. Wechsler Memory Scale-Revised Manual. San Antonio, TX: The Psychological Corporation, 1987.
26. Benton AL. Revised Visual Retention Test, 4th ed. New York, NY: Psychological Corporation, 1974.
27. Benedict RHB, Schretlen D, Groninger L, Brandt J. The hopkins verbal learning test-revised: Normative data and analysis of inter-form and test-retest reliability. The Clinical Neuropsychologist 1998;12:43-55.
28. Benton AL Silvan AB, Hamsher KdS, Varney NR, Spreen O. Contributions to Neuropsychological Assessment: A Clinical Manual. Lutz, FL: Psychological Assessment Resources, 1994.
29. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis: I. Segmentation and surface reconstruction. NeuroImage 1999;9:179-194. doi:10.1006/nimg.1998.0395.
30. Pinheiro JC, Bates DM. Mixed-effects models in S and S-PLUS. New York, NY: Springer, 2000.
31. Jenkinson M, Beckmann CF, Behrens TEJ, Woolrich MW, Smith SM. FSL. Neuroimage 2011. doi:10.1016/j.neuroimage.2011.09.015.
32. Smith SM. Fast robust automated brain extraction. Human Brain Mapping 2002;17:143-155.
33. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res 1996;29:162-173.
34. Abdi H, Williams LJ, Valentin D. Multiple factor analysis: principal component analysis for multitable and multiblock data sets. Wiley Interdisciplinary Reviews: Computational Statistics 2013;5:149-179. doi:10.1002/wics.1246.
35. Ibarretxe-Bilbao N, Junque C, Segura B, et al. Progression of cortical thinning in early Parkinson's disease. Mov Disord 2012;27:1746-1753. doi:10.1002/mds.25240.
36. Aslan S, Lu H. On the sensitivity of ASL MRI in detecting regional differences in cerebral blood flow. Magn Reson Imaging 2010;28:928-935. doi:10.1016/j.mri.2010.03.037.
37. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex 2009;19:497-510. doi:10.1093/cercor/bhn113.
38. Montine TJ, Shi M, Quinn JF, et al. CSF Aβ42 and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682-2685. doi:10.1002/mds.23287.
39. Sowell ER, Peterson BS, Kan E, et al. Sex differences in cortical thickness mapped in 176 healthy individuals between 7 and 87 years of age. Cereb Cortex 2007;17:1550-1560. doi:10.1093/cercor/bhl066.